



DAFTAR PUSTAKA

- Al-Daghri, N. M., Al-Attas, O., Alokail, M. S., Alkharfy, K. M., Draz, H. M., Agliardi, C., et al. (2012). Vitamin D Receptor Gene Polymorphisms and HLA DRB1*04 Cosegregation in Saudi Type 2 Diabetes Patients. *J Immunol*, 188 (3) 1325-1332; DOI: <https://doi.org/10.4049/jimmunol.1101954>.
- Annisa, A. (2017). Pengaruh Ketidakamanan Kerja, Kepuasan Kerja, dan Komitmen Organisasional Terhadap Turnover Intention Pada PT. Riau Crumb Rubber Factory (RICRY) Pekanbaru. *JOM Fekom*, Vo. 4, No.1, 364-375.
- Annisa, F., Nurhaeni, N., & Wanda, D. (2017). Warm Water Compress as an Alternative for Decreasing the Degree of Phlebitis. *Comprehensive Child and Adolescent Nursing*, 40(1), 107–113. <https://doi.org/10.1080/24694193.2017.1386978>
- Amelia Kurniati, Y. T. & S. I. M. T. (2018). *Keperawatan Gawat Darurat Dan Bencana Sheehy*. Singapore: Elsevier.
- Alandajani, A., Khalid, B., Ng, Y. G., & Banakhar, M. (2022). Knowledge and Attitudes Regarding Medication Errors among Nurses: A Cross-Sectional Study in Major Jeddah Hospitals. *Nursing Reports (Pavia, Italy)*, 12(4), 1023–1039. <https://doi.org/10.3390/nursrep12040098>
- Alexandrou, E., Ray-Barruel, G., Carr, P. J., Frost, S. A., Inwood, S., Higgins, N., Lin, F., Alberto, L., Mermel, L., & Rickard, C. M. (2018). Use of Short Peripheral Intravenous Catheters: Characteristics, Management, and Outcomes Worldwide. *Journal of Hospital Medicine*, 13(5), E1–E7. <https://doi.org/10.12788/jhm.3039>
- Aliyu, M., Zohora, F. T., Anka, A. U., Ali, K., Maleknia, S., Saffarioun, M., & Azizi, G. (2022). Interleukin-6 cytokine: An overview of the immune regulation, immune dysregulation, and therapeutic approach. *International Immunopharmacology*, 111, 109130. <https://doi.org/https://doi.org/10.1016/j.intimp.2022.109130>



- Annisa, F., Nurhaeni, N., & Wanda, D. (2017). Warm Water Compress as an Alternative for Decreasing the Degree of Phlebitis. *Comprehensive Child and Adolescent Nursing*, 40(1), 107–113. <https://doi.org/10.1080/24694193.2017.1386978>
- Aranow, C. (2011). Vitamin D and the immune system. *Journal of Investigative Medicine: The Official Publication of the American Federation for Clinical Research*, 59(6), 881–886. <https://doi.org/10.2310/JIM.0b013e31821b8755>
- Athanassiou, L., Mavragani, C. P., & Koutsilieris, M. (2022). The Immunomodulatory Properties of Vitamin D. *Mediterranean Journal of Rheumatology*, 33(1), 7–13. <https://doi.org/10.31138/mjr.33.1.7>
- Banda, Z., Simbota, M., & Mula, C. (2022). Nurses' perceptions on the effects of high nursing workload on patient care in an intensive care unit of a referral hospital in Malawi: a qualitative study. *BMC Nursing*, 21(1), 136. <https://doi.org/10.1186/s12912-022-00918-x>
- Bermudez, E. A., Rifai, N., Buring, J., Manson, J. E., & Ridker, P. M. (2002). Interrelationships Among Circulating Interleukin-6, C-Reactive Protein, and Traditional Cardiovascular Risk Factors in Women. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 22(10), 1668–1673. <https://doi.org/10.1161/01.ATV.0000029781.31325.66>
- Bester, J., & Pretorius, E. (2016). Effects of IL-1 β , IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity. *Scientific Reports*, 6(1), 32188. <https://doi.org/10.1038/srep32188>
- Beyranvand Nejad, E., Labrie, C., van Elsas, M. J., Kleinovink, J. W., Mittrücker, H.-W., Franken, K. L. M. C., Heink, S., Korn, T., Arens, R., van Hall, T., & van der Burg, S. H. (2021). IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors. *Journal for Immunotherapy of Cancer*, 9(4). <https://doi.org/10.1136/jitc-2021-002460>
- Biresaw, H., Asfaw, N., & Zewdu, F. (2020). Knowledge and attitude of nurses towards patient safety and its associated factors. *International*



- Journal of Africa Nursing Sciences*, 13, 100229.
<https://doi.org/https://doi.org/10.1016/j.ijans.2020.100229>
- Braga, L. M., Parreira, P. M., Oliveira, A. de S. S., Mónico, L. dos S. M., Arreguy-Sena, C., & Henriques, M. A. (2018). Phlebitis and infiltration: Vascular trauma associated with the peripheral venous catheter. *Revista Latino-Americana de Enfermagem*, 26.
<https://doi.org/10.1590/1518-8345.2377.3002>
- Chen, Y., Zhang, J., Ge, X., Du, J., Deb, D. K., & Li, Y. C. (2013). Vitamin D receptor inhibits nuclear factor κ B activation by interacting with I κ B kinase β protein. *The Journal of Biological Chemistry*, 288(27), 19450–19458. <https://doi.org/10.1074/jbc.M113.467670>
- Chowdhury, S., & Chakraborty, P. pratim. (2017). Universal health coverage - There is more to it than meets the eye. *Journal of Family Medicine and Primary Care*, 6(2), 169–170.
<https://doi.org/10.4103/jfmprc.jfmprc>
- de la Guía-Galipienso, F., Martínez-Ferran, M., Vallecillo, N., Lavie, C. J., Sanchis-Gomar, F., & Pareja-Galeano, H. (2021). Vitamin D and cardiovascular health. *Clinical Nutrition (Edinburgh, Scotland)*, 40(5), 2946–2957. <https://doi.org/10.1016/j.clnu.2020.12.025>
- Didion, S. P. (2017). Cellular and Oxidative Mechanisms Associated with Interleukin-6 Signaling in the Vasculature. *International Journal of Molecular Sciences*, 18(12). <https://doi.org/10.3390/ijms18122563>
- Diwakar, K., Kumar, S., Srivastava, P., Uddin, M. W., & Mishra, S. (2021). Reduction in the incidence of infusion-related phlebitis in a pediatric critical care unit of Eastern India: A quality improvement initiative. *Medical Journal Armed Forces India*, 80(1), 46–51.
<https://doi.org/10.1016/j.mjafi.2021.07.010>
- eHealthMe. (2022). *Vitamin d and Phlebitis - a phase IV clinical study of FDA data*. Phlebitis.
- Fadhilah, N., & Wulandari, H. (2021). Hubungan osmolaritas cairan infus dengan kejadian flebitis pada pasien neonatus di rs mitra husada



- pringsewu. *Healthcare Nursing Journal*, 3(2), 102–106.
- Fitriyanti, S. (2015). Faktor yang mempengaruhi terjadinya phlebitis di Rumah Sakit Bhayangkara Tk II. H. S. Samsoeri Mertojoso Surabaya. *Jurnal Berkala Epidemiologi*, 3(2), 217–229.
- García-Expósito, J., Reguant, M., Canet-Vélez, O., Ruiz Mata, F., Botigué, T., & Roca, J. (2021). Evidence of learning on the insertion and care of peripheral venous catheters in nursing students: A mixed study. *Nurse Education Today*, 107. <https://doi.org/10.1016/j.nedt.2021.105157>
- Guanche-Sicilia, A., Sánchez-Gómez, M. B., Castro-Peraza, M. E., Rodríguez-Gómez, J. Á., Gómez-Salgado, J., & Duarte-Clíments, G. (2021). Prevention and Treatment of Phlebitis Secondary to the Insertion of a Peripheral Venous Catheter: A Scoping Review from a Nursing Perspective. *Healthcare (Basel, Switzerland)*, 9(5). <https://doi.org/10.3390/healthcare9050611>
- Haddad Kashani, H., Seyed Hosseini, E., Nikzad, H., Soleimani, A., Soleimani, M., Tamadon, M. R., Keneshlou, F., & Asemi, Z. (2018). The Effects of Vitamin D Supplementation on Signaling Pathway of Inflammation and Oxidative Stress in Diabetic Hemodialysis: A Randomized, Double-Blind, Placebo-Controlled Trial. *Frontiers in Pharmacology*, 9, 50. <https://doi.org/10.3389/fphar.2018.00050>
- Hamarno, R., Herawati, T., & Suprayoga, B. (2019). Perawatan Luka Infus Terhadap Kejadian Phlebitis. *Journal of Applied Nursing (Jurnal Keperawatan Terapan)*, 5(1), 1. <https://doi.org/10.31290/jkt.v5i1.892>
- Han, L., Xu, X.-J., Zhang, J.-S., & Liu, H.-M. (2022). Association between Vitamin D Deficiency and Levels of Renin and Angiotensin in Essential Hypertension. *International Journal of Clinical Practice*, 2022, 8975396. <https://doi.org/10.1155/2022/8975396>
- Harbour, S. N., DiToro, D. F., Witte, S. J., Zindl, C. L., Gao, M., Schoeb, T. R., Jones, G. W., Jones, S. A., Hatton, R. D., & Weaver, C. T. (2020). T(H)17 cells require ongoing classic IL-6 receptor signaling to retain



- transcriptional and functional identity. *Science Immunology*, 5(49).
<https://doi.org/10.1126/sciimmunol.aaw2262>
- Hidayat, F., Labeda, I., Sampetoding, S., Pattelongi, I. J., Lusikooy, R. E., Warsinggih, Dani, M. I., Mappincara, Kusuma, M. I., Uwuratuw, J. A., Syarifuddin, E., & Faruk, M. (2021). Correlation of interleukin-6 and C-reactive protein levels in plasma with the stage and differentiation of colorectal cancer: A cross-sectional study in East Indonesia. *Annals of Medicine and Surgery* (2012), 62, 334–340.
<https://doi.org/10.1016/j.amsu.2021.01.013>
- Holick, M. F. (2013). Vitamin D: Physiology, Dietary Sources, and Requirements. *Encyclopedia of Human Nutrition*, 4–4, 370–382.
<https://doi.org/10.1016/B978-0-12-375083-9.00276-2>
- Huang, Y.-H., Yang, H.-Y., Huang, S.-W., Ou, G., Hsu, Y.-F., & Hsu, M.-J. (2016). Interleukin-6 Induces Vascular Endothelial Growth Factor-C Expression via Src-FAK-STAT3 Signaling in Lymphatic Endothelial Cells. *PLOS ONE*, 11(7), 1–18.
<https://doi.org/10.1371/journal.pone.0158839>
- Hung, K.-C., Yang, S.-H., Chang, C.-Y., Wang, L.-K., Lin, Y.-T., Yu, C.-H., Chuang, M.-H., & Chen, J.-Y. (2023). Is Circulating Vitamin D Status Associated with the Risk of Venous Thromboembolism? A Meta-Analysis of Observational Studies. *Nutrients*, 15(5).
<https://doi.org/10.3390/nu15051113>
- Jamal, Z., Umair, M., Zubair, R., Zafar, N., Rauf, F., & Affif, M. (2019). Peripheral Intravenous Catheter related Thrombophlebitis Incidence and Risk Factors A Cross Sectional Study. *Journal of Rawalpindi Medical College*, 23, 22–27.
- Kanugula, A. K., Kaur, J., Batra, J., Ankireddypalli, A. R., & Velagapudi, R. (2023). Renin-Angiotensin System: Updated Understanding and Role in Physiological and Pathophysiological States. *Cureus*, 15(6), e40725. <https://doi.org/10.7759/cureus.40725>
- Karami, A., Farokhzadian, J., & Foroughameri, G. (2017). Nurses'



- professional competency and organizational commitment: Is it important for human resource management? *PLOS ONE*, 12(11), 1–15. <https://doi.org/10.1371/journal.pone.0187863>
- Khademvatani, K., Seyyed-Mohammadzad, M. H., Akbari, M., Rezaei, Y., Eskandari, R., & Rostamzadeh, A. (2014). The relationship between vitamin D status and idiopathic lower-extremity deep vein thrombosis. *International Journal of General Medicinene*, 7, 303–309. <https://doi.org/10.2147/IJGM.S64812>
- Kim, D.-H., Meza, C. A., Clarke, H., Kim, J.-S., & Hickner, R. C. (2020). Vitamin D and Endothelial Function. *Nutrients*, 12(2). <https://doi.org/10.3390/nu12020575>
- Kim, S. S., Kaplowitz, S., & Johnston, M. V. (2004). The effects of physician empathy on patient satisfaction and compliance. *Evaluation & the Health Professions*, 27(3), 237–251. <https://doi.org/10.1177/0163278704267037>
- Korn, T., & Hiltensperger, M. (2021). Role of IL-6 in the commitment of T cell subsets. *Cytokine*, 146, 155654. <https://doi.org/https://doi.org/10.1016/j.cyto.2021.155654>
- Kwame, A., & Petrucka, P. M. (2021). A literature-based study of patient-centered care and communication in nurse-patient interactions: barriers, facilitators, and the way forward. *BMC Nursing*, 20(1), 158. <https://doi.org/10.1186/s12912-021-00684-2>
- Lee, S., Kim, K., & Kim, J. S. (2019). A Model of Phlebitis Associated with Peripheral Intravenous Catheters in Orthopedic Inpatients. *International Journal of Environmental Research and Public Health*, 16(18), 3412. <https://doi.org/10.3390/ijerph16183412>
- Li, G., Litscher, G., Pang, H., Yang, B., Litscher, D., & Wang, L. (2018). Experimental Study of Phlebitis Ointment Administration in Acute Superficial Thrombophlebitis. *Evidence-Based Complementary and Alternative Medicine : ECAM*, 2018, 2983195. <https://doi.org/10.1155/2018/2983195>



- Lidiana, E. H., Norman Wijaya Gati, & Sri Hartutik. (2023). Upaya Peningkatan Imunitas Tubuh Dalam Pencegahan Covid-19. *GEMASSIKA: Jurnal Pengabdian Kepada Masyarakat*, 7(1), 48–54. <https://doi.org/10.30787/gemassika.v7i1.853>
- Llado, Y., Lucy, M., Rodry, M. J., Garvi, L., Soler, E. E., Almendral, A., Limo, E., & Fuste, E. (2023). *Paket perawatan untuk pencegahan vena perifer infeksi aliran darah kateter di perawatan sekunder rumah sakit universitas : Implementasi dan hasil*. 28.
- Lin, S. W., Chen, S. C., Huang, F. Y., Lee, M. Y., & Chang, C. C. (2021) Effects of a clinically indicated peripheral intervenous replacement on indwelling time and complications of peripheral intervenous catheters in pediatric patients: a randomized controlled tril. *International Journal of Environmental Research and Public Health*, 18(7)3795
- Lu, Y., Hao, C., He, W., Tang, C., & Shao, Z. (2018). Experimental research on preventing mechanical phlebitis arising from indwelling needles in intravenous therapy by external application of mirabilite. *Experimental and Therapeutic Medicine*, 15(1), 276–282. <https://doi.org/10.3892/etm.2017.5347>
- Lv, L., & Zhang, J. (2020). The incidence and risk of infusion phlebitis with peripheral intravenous catheters: A meta-analysis. *Journal of Vascular Access*, 21(3), 342–349. <https://doi.org/10.1177/1129729819877323>
- Maragani, E. J., Marethalia, F., Margareth, L., Eka, N. G. A., & Manihuruk, G. A. M. (2021). Faktor Risiko Eksternal Kejadian Phlebitis Pada Pemasangan Kateter Intravena Perifer: Studi Dokumentasi. *Jurnal Muara Sains, Teknologi, Kedokteran Dan Ilmu Kesehatan*, 5(2), 467. <https://doi.org/10.24912/jmstkik.v5i2.11923>
- Maryunani, A. (2019). *PLEBITIS DAN KOMPLIKASI LAINNYA*. IN MEDIA.
- Masfufatun, M., Tania, P. O. A., Raharjo, L. H., & Baktir, A. (2018). Kadar IL-6 dan IL-10 Serum pada Tahapan Inflamasi di Rattus norvegicus yang terinfeksi Candida albicans. *Jurnal Kedokteran Brawijaya*, 30(1), 19. <https://doi.org/10.21776/ub.jkb.2018.030.01.4>



- Matheu, V., Bäck, O., Mondoc, E., & Issazadeh-Navikas, S. (2003). Dual effects of vitamin D-induced alteration of TH1/TH2 cytokine expression: enhancing IgE production and decreasing airway eosinophilia in murine allergic airway disease. *The Journal of Allergy and Clinical Immunology*, 112(3), 585–592. [https://doi.org/10.1016/s0091-6749\(03\)01855-4](https://doi.org/10.1016/s0091-6749(03)01855-4)
- Mauer, J., Denson, J. L., & Bruning, J. C. (2015). Versatile functions for IL-6 in metabolism and cancer. *Trends in Immunology*, 36(2), 92–101. <https://doi.org/https://doi.org/10.1016/j.it.2014.12.008>
- Mazanava, A., Shymanskyi, I., Lisakovska, O., Labudzynski, D., Khomenko, A., & Veliky, M. (2022). The link between vitamin D status and NF- κ B-associated renal dysfunction in experimental diabetes mellitus. *Biochimica et Biophysica Acta. General Subjects*, 1866(7), 130136. <https://doi.org/10.1016/j.bbagen.2022.130136>
- Montgomery, A., Tam, F., Gursche, C., Cheneval, C., Besler, K., Enns, W., Manku, S., Rey, K., Hanson, P. J., Rose-John, S., McManus, B. M., & Choy, J. C. (2021). Overlapping and distinct biological effects of IL-6 classic and trans-signaling in vascular endothelial cells. *American Journal of Physiology. Cell Physiology*, 320(4), C554–C565. <https://doi.org/10.1152/ajpcell.00323.2020>
- Mroczkowska, R. (2015). *Nosocomial infections in the aspect of medical service quality in Poland and worldwide*. May. <https://doi.org/10.13140/RG.2.1.1905.8086>
- Munandar, F. (2021). Aspek Klinis dan Tatalaksana Hipernatremia Pada Anak. *Jurnal Implementa Husada*, 2(4), 13–19. <https://doi.org/10.30596/jih.v2i4.11864>
- Naeini, A. E., Moeinzadeh, F., Vahdat, S., Ahmadi, A., Hedayati, Z. P., & Shahzeidi, S. (2017). The Effect of Vitamin D Administration on Intracellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1 Levels in Hemodialysis Patients: A Placebo-controlled, Double-blinded Clinical Trial. *Journal of Research in Pharmacy*



- Practice*, 6(1), 16–20. <https://doi.org/10.4103/2279-042X.200994>
- Nobre, A. S. P., & Martins, M. D. da S. (2018). Prevalence of peripheral intravenous catheter-related phlebitis: associated factors. *ERvista de Enfermagem Referência*, IV(16). <https://doi.org/https://doi.org/10.12707/RIV17058>
- Okky, P., Tania, A., Simamora, D., Dyah Parmasari, W., Rahmawati, F., Biomedik, B., Biomolekuler, P., Kedokteran, F., Wijaya, U., Surabaya, K., Gigi, B., Mulut, D., Patologi, B., Fakultas, K., Universitas, K., & Surabaya, W. K. (2014). Kadar Interleukin 6 (Il-6) Sebagai Indikator Progresivitas Penyakit Reumatoid Arthritis (Ra). *Ilmiah Kedokteran*, 3, 40–47.
- Oleksowicz, L., Mrowiec, Z., Zuckerman, D., Isaacs, R., Dutcher, J., & Puszkin, E. (1994). Platelet activation induced by interleukin-6: evidence for a mechanism involving arachidonic acid metabolism. *Thrombosis and Haemostasis*, 72(2), 302–308.
- Onofrei, L., Serban, C. L., Chirita-Emandi, A., Jeleriu, R. M., & Puiu, M. (2023). The impact of theory of mind, stress and professional experience on empathy in Romanian community nurses-a cross-sectional study. *BMC Nursing*, 22(1), 400. <https://doi.org/10.1186/s12912-023-01569-2>
- Parawangsa, A., Sugito, S. K., Ayu Ananda Latifa, A., Dinda Safira, N., Ayuthaya, S., & Rahmalia Az Zahra, R. (2022). Molecular docking of Vitamin D3 Receptor (VDR) with potential herbal substance as ligand to prevent excessive hair loss in menopausal women. *Indonesian Journal of Medical Chemistry and Bioinformatics*, 1(1), 1–7. <https://doi.org/10.7454/ijmcb.v1i1.1010>
- Poredoš, P., Spirkoska, A., & Ježovnik, M. K. (2019). In patients with superficial vein thrombosis the inflammatory response is increased and related to the recanalization rate. *Arch Med Sci*, 15, 393–401. <https://doi.org/https://doi.org/10.5114/aoms.2019.83292>
- Puspitasari, S. C. (2018). Pengaruh Ekstrak Kulit Buah Naga Merah



- (Hylocereus Polyrhizus) Terhadap Kadar Interleukin-6 Mencit Model Endometriosis. *Jurnal Biosains Pascasarjana*, 19(3), 197. <https://doi.org/10.20473/jbp.v19i3.2017.197-210>
- Ramasamy, I. (2020). Vitamin D Metabolism and Guidelines for Vitamin D Supplementation. *The Clinical Biochemist. Reviews*, 41(3), 103–126. <https://doi.org/10.33176/AACB-20-00006>
- Rasheed, A., Siddiqui, F., Yaqoob, M., Masih, S., Rehan, M., Khan, R. A., Ahmed, F., Rehan, M., Qasim, R., Rasheed, A., Yaqoob, M., Masih, S., Rehan, M., & Qasim, R. (2023). *Flebitis akibat kateter intravena perifer di rumah sakit tersier Karachi : Sebuah studi kohort Penyebab Phlébite dari Kateter Intraveineux Periferal di Rumah Sakit Tertiaire di Karachi : Studi Kel. November*. <https://doi.org/10.5737/va.v17i2.9>
- Rautenbach, P. H., Nienaber-Rousseau, C., de Lange-Loots, Z., Kruger, I. M., & Pieters, M. (2022). Associations Between 25-Hydroxyvitamin D and Total and γ' Fibrinogen and Plasma Clot Properties and Gene Interactions in a Group of Healthy Black South African Women. *Frontiers in Cardiovascular Medicine*, 9, 868542. <https://doi.org/10.3389/fcvm.2022.868542>
- Ray-Barruel, G., Chopra, V., Fulbrook, P., Lovegrove, J., Mihala, G., Wishart, M., Cooke, M., Mitchell, M., & Rickard, C. M. (2023). The impact of a structured assessment and decision tool (I-DECIDED®) on improving care of peripheral intravenous catheters: A multicenter, interrupted time-series study. *International Journal of Nursing Studies*, 148. <https://doi.org/10.1016/j.ijnurstu.2023.104604>
- Rizal, A. A. F., & Khotimah, H. (2018). Hubungan Antara Lokasi Penusukan dengan Kejadian Plebitis pada Pasien di Ruang Flamboyan RSUD Abdul Wahab Sjahranie Samarinda. *Jurnal Ilmu Kesehatan*, 6(1), 10–17.
- Roffe-Vazquez, D. N., Huerta-Delgado, A. S., Castillo, E. C., Villarreal-Calderón, J. R., Gonzalez-Gil, A. M., Enriquez, C., Garcia-Rivas, G., & Elizondo-Montemayor, L. (2019). Correlation of Vitamin D with



- Inflammatory Cytokines, Atherosclerotic Parameters, and Lifestyle Factors in the Setting of Heart Failure: A 12-Month Follow-Up Study. *International Journal of Molecular Sciences*, 20(22). <https://doi.org/10.3390/ijms20225811>
- Saini, C., Srivastava, R. K., Tarique, M., Kurra, S., Khanna, N., Ramesh, V., & Sharma, A. (2020). Elevated IL-6R on CD4+ T cells promotes IL-6 driven Th17 cell responses in patients with T1R leprosy reactions. *Scientific Reports*, 10(1), 15143. <https://doi.org/10.1038/s41598-020-72148-7>
- Sassi, F., Tamone, C., & D'amelio, P. (2018). Vitamin D: Nutrient, hormone, and immunomodulator. *Nutrients*, 10(11), 1–14. <https://doi.org/10.3390/nu10111656>
- Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011). The pro- and anti-inflammatory properties of the cytokine interleukin-6. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research*, 1813(5), 878–888. <https://doi.org/https://doi.org/10.1016/j.bbamcr.2011.01.034>
- Sebina, I., Fogg, L. G., James, K. R., Soon, M. S. F., Akter, J., Thomas, B. S., Hill, G. R., Engwerda, C. R., & Haque, A. (2017). IL-6 promotes CD4(+) T-cell and B-cell activation during Plasmodium infection. *Parasite Immunology*, 39(10). <https://doi.org/10.1111/pim.12455>
- Sen, A., Vincent, V., Thakkar, H., Abraham, R., & Ramakrishnan, L. (2022). Beneficial Role of Vitamin D on Endothelial Progenitor Cells (EPCs) in Cardiovascular Diseases. *Journal of Lipid and Atherosclerosis*, 11(3), 229–249. <https://doi.org/10.12997/jla.2022.11.3.229>
- Senchenkova, E. Y., Komoto, S., Russell, J., Almeida-Paula, L. D., Yan, L.-S., Zhang, S., & Granger, D. N. (2013). Interleukin-6 mediates the platelet abnormalities and thrombogenesis associated with experimental colitis. *The American Journal of Pathology*, 183(1), 173–181. <https://doi.org/10.1016/j.ajpath.2013.03.014>



- Setyawan, F. E. B., Supriyanto, S., Tunjungsari, F., Hanifaty, W. O. N., & Lestari, R. (2019). Medical staff services quality to patients satisfaction based on SERVQUAL dimensions. *International Journal of Public Health Science (IJPHS)*, 8(1), 51. <https://doi.org/10.11591/ijphs.v8i1.17066>
- Sizar, O., Khare, S., Goyal, A., & et al. (2023). Vitamin D Deficiency. In *StatPearls [Internet]*. StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK532266/>
- Soleimani, M., Jameie, S. B., Mehdizadeh, M., Keradi, M., Masoumipoor, M., & Mehrabi, S. (2014). Vitamin D3 influence the Th1/Th2 ratio in C57BL/6 induced model of experimental autoimmune encephalomyelitis. *Iranian Journal of Basic Medical Sciences*, 17(10), 785–792.
- Souza, A. E. B. R. de, Oliveira, J. L. C. de, Dias, D. C., & Nicola, A. L. (2015). Prevalência de flebites em pacientes adultos internados em hospital universitário. *Artigo Original*, 16(1). <https://doi.org/DOI:10.15253/2175-6783.2015000100015>
- Syarifuddin Wahid at all. (2015). *Imunologi Lebih Mudah Dipahami*. Brillian International.
- Tanaka, T., Narazaki, M., & Kishimoto, T. (2014). IL-6 in inflammation, immunity, and disease. *Cold Spring Harbor Perspectives in Biology*, 6(10), a016295. <https://doi.org/10.1101/cshperspect.a016295>
- Thompson, B., Waterhouse, M., English, D. R., McLeod, D. S., Armstrong, B. K., Baxter, C., Romero, B. D., Ebeling, P. R., Hartel, G., Kimlin, M. G., Rahman, S. T., van der Pols, J. C., Venn, A. J., Webb, P. M., Whiteman, D. C., & Neale, R. E. (2023). Vitamin D supplementation and major cardiovascular events: D-Health randomised controlled trial. *BMJ*, 381. <https://doi.org/10.1136/bmj-2023-075230>
- Tristão, F. S. M., Rocha, F. A., Carlos, D., Ketelut-Carneiro, N., Souza, C. O. S., Milanezi, C. M., & Silva, J. S. (2017). Th17-Inducing Cytokines IL-6 and IL-23 Are Crucial for Granuloma Formation during



- Experimental Paracoccidioidomycosis. *Frontiers in Immunology*, 8, 949. <https://doi.org/10.3389/fimmu.2017.00949>
- Urbanetto, J. de S., Freitas, A. P. C. de, Oliveira, A. P. R. de, Santos, J. de C. R. Dos, Muniz, F. de O. M., Silva, R. M. da, & Schilling, M. C. L. (2018). Risk factors for the development of phlebitis: an integrative review of literature. *Revista Gaucha de Enfermagem*, 38(4), e57489. <https://doi.org/10.1590/1983-1447.2017.04.57489>
- Urbanetto, J. de S., Peixoto, C. G., & May, T. A. (2016). Incidência de flebitis durante o uso e após a retirada de cateter intravenoso periférico. *Revista Latino-Americana de Enfermagem*, 24. <https://doi.org/10.1590/1518-8345.0604.2746>
- Vgontzas, A. N., Bixler, E. O., Lin, H.-M., Prolo, P., Trakada, G., & Chrousos, G. P. (2005). IL-6 and its circadian secretion in humans. *Neuroimmunomodulation*, 12(3), 131–140. <https://doi.org/10.1159/000084844>
- West, M., Wantz, D., Campbell, P., Rosler, G., Troutman, D., & Muthler, C. (2016). Contributing to a Quality Patient Experience: Applying Evidence Based Practice to Support Changes in Nursing Dress Code Policies. *OJIN: The Online Journal of Issues in Nursing*, 21(4). <https://ojin.nursingworld.org/MainMenuCategories/ANAMarketplace/ANAPeriodicals/OJIN/TableofContents/Vol-21-2016/No-1-Jan-2016/Articles-Previous-Topics/Articles-Previous-Topics/Contributing-to-a-Quality-Patient-Experience.html>
- White, J. H. (2022). Emerging Roles of Vitamin D-Induced Antimicrobial Peptides in Antiviral Innate Immunity. *Nutrients*, 14(2). <https://doi.org/10.3390/nu14020284>
- Wijayanti, R., & Nuraini, N. (2018). Peningkatan Mutu Pelayanan Rawat Inap melalui Penanggulangan Phlebitis di Klinik Dr. M. Suherman Jember. *Prosiding*, 3(0), 156–160.
- Xiang-FengLi, Liu, W., & Qin, Y. (2016). Nurses' perception of risk factors for infusion phlebitis: A cross-sectional survey. *Chinese Nursing*



- Research*, 3(1), 37–40. <https://doi.org/10.1016/j.cnre.2016.03.002>
- Xie, J., & Ma, S. (2023). Research on the service quality of emergency medical language services during major unexpected public health events. *Frontiers in Public Health*, 11, 1169222. <https://doi.org/10.3389/fpubh.2023.1169222>
- Xu, H., Keogh, S., Ullman, A. J., Marsh, N., Tobiano, G., Rickard, C. M., Clark, J., & Griffin, B. (2023). Implementation frameworks, strategies and outcomes used in peripheral intravenous catheter studies: A systematic review. *Journal of Clinical Nursing*, 32(17–18), 6706–6722. <https://doi.org/10.1111/jocn.16671>
- Yang, Y.-C., Fu, H., Zhang, B., & Wu, Y.-B. (2022). Interleukin-6 Downregulates the Expression of Vascular Endothelial-Cadherin and Increases Permeability in Renal Glomerular Endothelial Cells via the Trans-Signaling Pathway. *Inflammation*, 45(6), 2544–2558. <https://doi.org/10.1007/s10753-022-01711-3>
- Yin, K., & Agrawal, D. K. (2014). Vitamin D and inflammatory diseases. *Journal of Inflammation Research*, 7, 69–87. <https://doi.org/10.2147/JIR.S63898>
- Youssef, D. A., Miller, C. W., El-Abbassi, A. M., Cutchins, D. C., Cutchins, C., Grant, W. B., & Peiris, A. N. (2011). Antimicrobial implications of vitamin D. *Dermato-Endocrinology*, 3(4), 220–229. <https://doi.org/10.4161/derm.3.4.15027>
- Yu, C. C., Tan, L., LE, M. K., Tang, B., Liaw, S. Y., Tierney, T., Ho, Y. Y., Lim, B. E. E., Lim, D., Ng, R., Chia, S. C., & Low, J. A. (2022). The development of empathy in the healthcare setting: a qualitative approach. *BMC Medical Education*, 22(1), 245. <https://doi.org/10.1186/s12909-022-03312-y>
- Wira Darmatasia.(2012).PERAN VITAMIN D DALAMREGULASI SISTEM IMUNITAS MELALUI SEL DENDRITIK. *Jurnal Ilmiah Kesehatan Media Husada Volume 01*.



WHO. (2018). *The Top 10 Causes of Death*. Retrieved September 24, 2018, from WHO Web Site: <http://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causes-of-death>



Lampiran 1:

SURAT KETERANGAN PENGAMBILAN DATA AWAL



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET
DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN
FAKULTAS KEDOKTERAN
PROGRAM STUDI DOKTOR ILMU KEDOKTERAN
Jl. Perintis Kemerdekaan Km. 10 Makassar 90245 Telp.(0411)586010,(0411)586297
s3kedokteranunhas@gmail.com

Nomor : 473/UN4.6.8/PT.01.04/2023
Lampiran : 1 (Satu) Rangkap
Perihal : Permohonan Izin Penelitian

13 Januari 2023

Yth.
Direktur Utama Rumah Sakit Ibnu Sina
Direktur Utama Rumah Sakit Labuang Baji
Makassar

Dengan hormat kami sampaikan bahwa mahasiswa Fakultas Kedokteran Program Studi Doktor Ilmu Kedokteran Universitas Hasanuddin yang tersebut dibawah ini :

Nama : **Andi Mappanganro**
Nomor Pokok : C013201003
Program Pendidikan : Doktor (S3)
Program Studi : Ilmu Kedokteran

Bermaksud melakukan penelitian dalam rangka penulisan disertasi doktor dengan Judul penelitian :
Analisis Kualitas Layanan Keperawatan dan Kadar Vitamin D Reseptor, Interleukin 6 terhadap Kejadian
Plebitis pada Pasien Terpasang Infus di RS Labuang Baji dan RS Ibnu Sina Makassar.

Sehubungan dengan hal tersebut kami mohon kiranya berkenan memberikan izin untuk melakukan
Penelitian di Instansi Bapak/Ibu. Data yang diperoleh hanya digunakan untuk kepentingan penelitian dan
akan dijaga kerahasiaannya.

Ketua Program Studi S3
Ilmu Kedokteran

Dr. dr. Irfan Idris, M.Kes
NIP. 196711031998021001

Tembusan Yth :

1. Wakil Dekan Bidang Akademik dan Kemahasiswaan FK Unhas
2. Arsip



Lampiran 2:

SURAT REKOMENDASI PERSETUJUAN ETIK



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
 UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
 KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
 RSPN UNIVERSITAS HASANUDDIN
 RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
 JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.



Contact Person: dr. Agussalim Bukhari, MMed, PhD, SpGK, TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 76/UN4.6.4.5.31/ PP36/ 2023

Tanggal: 31 Januari 2023

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH22120798	No Sponsor Protokol	
Peneliti Utama	Andi Mappanganro, S.Kep, Ns, M.Kep	Sponsor	
Judul Peneliti	Analisis Kualitas Layanan Keperawatan dan Kadar Vitamin D Reseptor, Interleukin 6 terhadap kejadian plebitis Pada pasien terpasang infus di RS labuang baji dan RS Ibnu Sina Makassar.		
No Versi Protokol	2	Tanggal Versi	27 Januari 2023
No Versi PSP	2	Tanggal Versi	27 Januari 2023
Tempat Penelitian	RS Labuang Baji dan RS Ibnu Sina Makassar.		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 31 Januari 2023 sampai 31 Januari 2024	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan 	
Sekretaris KEP Universitas Hasanuddin	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan 	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan



Lampiran 3:

LEMBAR PERSETUJUAN RESPONDEN

Judul penelitian: **Analisis kualitas layanan keperawatan dan kadar vitamin D reseptor, interlukin 6 terhadap kejadian plebitis pada pasien terpasang infus di RS Labuang Baji dan RS Ibnu Sina Makassar**

Peneliti : Andi Mappanganro

Nim : C013201003

Berdasarkan penjelasan yang telah disampaikan oleh peneliti tentang penelitian yang akan dilaksanakan sesuai judul yang tersebut diatas, saya mengetahui bahwa tujuan menganalisis kualitas layanan keperawatan dan kadar vitamin d reseptor, interlukin 6 terhadap kejadian plebitis pada pasien terpasang infus di RS Ibnu Sina Makassar.

Saya memahami bahwa keikutsertaan saya dalam penelitian ini sangat besar manfaatnya bagi peningkatan kualitas pelayanan keperawatan khususnya dalam perawatan luka kaki diabetik sehingga dapat meningkatkan mutu pelayanan keperawatan.

Saya memahami bahwa risiko yang akan terjadi sangat kecil dan saya berhak untuk menghentikan keikutsertaan saya dalam penelitian ini tanpa mengurangi hak-hak saya mendapatkan pelayanan perawatan kesehatan.

Saya juga mengerti bahwa catatan mengenai penelitian ini akan dijamin kerahasiaannya, semua berkas yang mencantumkan identitas subjek penelitian hanya akan digunakan untuk keperluan pengolahan data dan bila sudah tidak digunakan akan dimusnahkan serta hanya peneliti yang mengetahui kerahasiaan data tersebut.

Selanjutnya secara suka rela dan tidak ada unsur paksaan dari siapapun, dengan ini saya menyatakan bersedia berpartisipasi dalam penelitian ini.

Responden

Makassar, April 2022

(.....)

Andi Mappanganro



Lampiran 4:

LEMBAR OBSERVASI

Judul Penelitian : **Analisis kualitas layanan keperawatan dan kadar vitamin D reseptor, interleukin 6 terhadap kejadian plebitis pada pasien terpasang infus di RS Ibnu Sina Makassar.**

Inisial :
Kode Responden :
Diagnosa Medis :
No. RM :
Pekerjaan :
Pendidikan :

Petunjuk Pengisian :

1. Bacalah dengan teliti seluruh petunjuk dibawah ini.
2. Mohon jawab seluruh pertanyaan dibawah ini
3. Beri tanda (x) pada pilihan jawaban yang sesuai pilihan.

Pertanyaan.

1. Tanggal pemasangan :
2. Jam Pemasangan :
3. Umur (... ..Th)
4. Jenis kelamin
a. Laki – laki b. Perempuan
5. Lokasi Pemasangan
 Vena sefalika
 Vena basilika
 Vena metacarpal
 Vena dorsal pedis
 Vena tibialis posterior



6. Observasi kejadian plebitis

Kejadian Phlebitis						
Perawatan (Jam)	Tidak Phlebitis Derajat (0)	Phlebitis Derajat (1)	Phlebitis Derajat (2)	Phlebitis Derajat (3)	Phlebitis Derajat (4)	Phlebitis Derajat (5)
Ke 24						
Ke 48						
Ke 72						

Keterangan :

Derajat 0 : Tidak ada tanda/gejala *Phlebitis*

Derajat 1 : Terdapat salah satu gejala nyeri area suntikan atau eritema/kemerahan

Derajat 2 : Terdapat dua dari tanda berupa nyeri area suntikan, eritema dan pembengkakan di area penusukan

Derajat 3 : Terdapat semua dari tanda berupa nyeri sepanjang kanula, eritema, dan pembengkakan

Derajat 4 : Terdapat semua dari tanda berupa nyeri sepanjang canula, eritema, indurasi, dan tonjolan pembuluh darah vena yang abnormal

Derajat 5 : Terdapat semua dari tanda berupa nyeri sepanjang canula, eritema, indurasi, dan tonjolan pembuluh darah vena yang abnormal, panas yang tinggi.

Visual Infusion Plebitis/VIP score

Skor visual flebitis V. I. P. Score (Visual infusion phlebitis score)		
	Tempat suntikan tampak sehat.	0 Tak ada tanda flebitis ■ OBSERVASI KANULA
	Salah satu dari berikut jelas: Nyeri pada tempat suntikan Eritema pada tempat suntikan	1 Mungkin tanda dini flebitis ■ OBSERVASI KANULA
	Dua dari berikut jelas: Nyeri - Eritema - Pembengkakan	2 Stadium dini flebitis ■ Ganti tempat kanula
	Semua dari berikut jelas: Nyeri sepanjang kanula - Eritema Indurasi	3 Stadium moderat flebitis ■ GANTI KANULA ■ PIKIRKAN TERAPI
	Semua dari berikut jelas: Nyeri sepanjang kanula - Eritema Indurasi - Venous cord teraba	4 Stadium lanjut atau awal tromboflebitis ■ GANTI KANULA ■ PIKIRKAN TERAPI
	Semua dari berikut jelas: Nyeri sepanjang kanula - Eritema Indurasi - Venous cord teraba demam	5 Stadium lanjut tromboflebitis ■ LAKUKAN TERAPI ■ GANTI KANULA



7. Lembar Observasi Kualitas Layanan Keperawatan di ruang IGD dan berlanjut ruang Perawatan

No	Pernyataan	Ya (Sesuai SOP)	Ya (Tidak Sesuai SOP)	Tidak (Tidak dilakukan Sama sekali)	Keterangan
Reability (Kehandalan)					
1	Dilakukan proses desinfeksi pada lokasi penusukan				
2	Dilakukan pemilihan vena dengan lokasi penusukan yang tepat				
3	Pemilihan kateter intravena dengan ukuran tepat				
4	Tetesan infus sesuai indikasi				
5	Dilakukan teknik <i>dressing</i> intravena				
Assurance/ jaminan					
6	Pasien menerima <i>informed consent</i> dari perawat				
7	Pasien dipasang infus sesuai tahapan SOP pemasangan infus				
8	Perawat merespon keluhan pasien				
9	Perawat menanamkan kepercayaan kepada pasien dan keluarga				



10	Perawat menjaga keamanan pasien selama perawatan (keamanan fiksasi infus pasien)				
No	Pernyataan	Ya (Sesuai SOP)	Ya (Tidak Sesuai SOP)	Tidak (Tidak dilakukan Sama sekali)	Keterangan
Tangibles / tampilan fisik					
11.	Kesesuaian Infus set yang digunakan				Makro untuk pasien dewasa, mikro untuk anak-anak <input type="checkbox"/> Macro drip set <input type="checkbox"/> Micro drip set <input type="checkbox"/> Tranfusion set Catatan Lainnya :
12.	Kesesuaian cateter intra vena yang digunakan pada pasien.				Terpasang: <input type="checkbox"/> Size 14 <input type="checkbox"/> Size 16 <input type="checkbox"/> Size 18 <input type="checkbox"/> Size 20 <input type="checkbox"/> Size 22 <input type="checkbox"/> Size 24 Catatan Lainnya :



13.	Cairan yang terpasang sesuai dengan order/indikasi				Cairan yang digunakan : <input type="checkbox"/> Osmolaritas cairan/ obat (< 900mmol) : Ringer Laktat (RL)/NaCL, dll <input type="checkbox"/> Osmolaritas cairan/ obat (>900mmol) : Transfusi Cairan lain (tuliskan) Catatan Lainnnya :
14	Dilakukan persiapan seusai dengan SOP				
15	Dilakukan persiapan pasien dan alat				
No	Responsiveness	Tanggap	Cukup Tanggap	Tidak Tanggap	Keterangan
16	Ketanggapan perawat terhadap keluhan pasien				
17	Respon time perawat <input type="checkbox"/> Segera <input type="checkbox"/> 1 – 5 menit <input type="checkbox"/> Lebih dari 5 menit (tuliskan)				
		Sering	Jarang	Tidak Pernah	Keterangan
18	Perawat				



	menyediakan waktu untuk membantu pasien berjalan, BAK, BAB, ganti posisi tidur, dan lainnya				
19	Perawat bersedia menawarkan bantuan ketika pasien mengalami kesulitan walaupun tanpa diminta				
20	Perawat siaga melayani pasien diluar dari jadwal rutin (jadwal injeksi dll)				
	Emphy/ Kepedulian				
21	Perawat sering menengok dan memeriksa keadaan pasien seperti mengukur tensi, suhu, nadi pernapasan dan cairan infus				
22	Perawat perhatian dan memberikan dukungan moral (menanyakan dan berbincang-bincang tentang keadaan pasien termasuk perawatan infus)				
23	Perawat melihat kondisi pasien dan menanyakan keadaan pasien (terutama setelah dilakukan tindakan)				
No.	Pernyataan	Total Care = 3 – 4 jam	Partial Care = 2 – 3 jam	Minimal Care = 1 – 2 jam	Keterangan



24	Rata-rata standar waktu pelayanan perawat untuk pasien. Didapatkan dari rata-rata frekuensi dan lama kunjungan perawat selama perawatan.				
25	Perawat membantu pasien memenuhi kebutuhan dasarnya selama dirawat				

Kejadian phlebitis

Perawatan jam ke 24

- Tidak phlebitis derajat 0
- Phlebitis derajat 1
- Phlebitis derajat 2
- Phlebitis derajat 3
- Phlebitis derajat 4
- Phlebitis derajat 5

Perawat jam ke 48

- Tidak phlebitis derajat 0
- Phlebitis derajat 1
- Phlebitis derajat 2
- Phlebitis derajat 3
- Phlebitis derajat 4
- Phlebitis derajat 5

Perawatan jam ke 60 - 72

- Tidak phlebitis derajat 0
- Phlebitis derajat 1



- Phlebitis derajat 2
- Phlebitis derajat 3
- Phlebitis derajat 4
- Phlebitis derajat 5

Lampiran 5:

No	No. Sampel	Status Sampel	Hasil Elisa	
			VDR (ng/ml)	IL6 (pg/ml)
1	P01	Phlebitis	11.34	1471.02
2	P02	Phlebitis	18.73	1238.5
3	P03	Phlebitis	10.35	1430.62
4	P04	Phlebitis	10.04	1259.69
5	P05	Phlebitis	10.58	1488.55
6	P06	Phlebitis	11.73	1471.02
7	P07	Phlebitis	9.21	1283.76
8	P08	Phlebitis	14.23	1286.45
9	P09	Phlebitis	10.5	1379.71
10	P10	Phlebitis	11.19	1407.86
11	P11	Phlebitis	10.65	1321.68
12	P12	Phlebitis	18.97	1142.73
13	P13	Phlebitis	11.42	1289.14
14	P14	Phlebitis	9.21	1500.32
15	P15	Phlebitis	14.55	1453.62
16	P16	Phlebitis	18	1158.02
17	P17	Phlebitis	18.24	1393.74
18	P18	Phlebitis	9.58	1396.56
19	P19	Phlebitis	10.65	1465.21
20	P20	Phlebitis	11.58	1442.09
21	P21	Phlebitis	9.93	1277.77
22	P22	Phlebitis	10.16	1407.4
23	P23	Phlebitis	10.85	1486.43
24	P24	Phlebitis	18.34	1117.23
25	P25	Phlebitis	11.01	1463.57
26	P26	Phlebitis	10.78	1503.73
27	P27	Phlebitis	11.01	1429.71
28	P28	Phlebitis	11.01	1379.81
29	P29	Phlebitis	10.54	1415.74
30	P30	Phlebitis	9.69	1452.23
31	P31	Phlebitis	11.94	1415.74
32	P32	Phlebitis	8.85	1452.23



33	P33	Phlebitis	9.93	1415.74
34	P34	Phlebitis	10.54	1452.23
35	P35	Phlebitis	12.02	1424.11
36	P36	Phlebitis	9.93	1429.71
37	P37	Phlebitis	11.01	1298.9
38	P38	Phlebitis	10.7	1457.89
39	P39	Phlebitis	11.24	1452.23
40	P40	Phlebitis	10	1497.95
41	NP01	Non Phlebitis	32.35	718.58
42	NP02	Non Phlebitis	26.85	662.65
43	NP03	Non Phlebitis	31.56	684.97
44	NP04	Non Phlebitis	30.76	664.88
45	NP05	Non Phlebitis	26.08	720.82
46	NP06	Non Phlebitis	23.28	716.33
47	NP07	Non Phlebitis	29.36	658.2
48	NP08	Non Phlebitis	22.53	667.11
49	NP09	Non Phlebitis	31.82	658.2
50	NP10	Non Phlebitis	31.47	678.27
51	NP11	Non Phlebitis	30.85	653.74
52	NP12	Non Phlebitis	30.32	718.58
53	NP13	Non Phlebitis	30.41	845.93
54	NP14	Non Phlebitis	31.56	864.43
55	NP15	Non Phlebitis	30.68	678.27
56	NP16	Non Phlebitis	31.2	700.63
57	NP17	Non Phlebitis	30.85	800.04
58	NP18	Non Phlebitis	27.28	996.76
59	NP19	Non	30.85	768.21



		Phlebitis		
60	NP20	Non Phlebitis	23.54	725.32
61	NP21	Non Phlebitis	26.45	728.36
62	NP22	Non Phlebitis	27.12	715.02
63	NP23	Non Phlebitis	25.62	723.91
64	NP24	Non Phlebitis	27.21	644.23
65	NP25	Non Phlebitis	26.87	712.8
66	NP26	Non Phlebitis	26.37	646.44
67	NP27	Non Phlebitis	31.1	939.7
68	NP28	Non Phlebitis	31.1	743.95
69	NP29	Non Phlebitis	26.2	717.24
70	NP30	Non Phlebitis	29.57	790.98
71	NP31	Non Phlebitis	30.33	840.72
72	NP32	Non Phlebitis	31.44	706.14
73	NP33	Non Phlebitis	27.04	721.69
74	NP34	Non Phlebitis	26.96	721.69
75	NP35	Non Phlebitis	23.14	928.06
76	NP36	Non Phlebitis	31.27	692.84
77	NP37	Non Phlebitis	27.21	712.8
78	NP38	Non Phlebitis	31.78	688.42
79	NP39	Non Phlebitis	23.3	781.99
80	NP40	Non Phlebitis	21.91	697.28



Lampiran 6

Lampiran Uji Statistik

Jenis Kelamin * Kejadian Phlebitis

Crosstab

			Kejadian Phlebitis		Total
			Ya	Tidak	
Jenis Kelamin	Laki-laki	Count	29	29	58
		% within Jenis Kelamin	50.0%	50.0%	100.0%
		% within Kejadian Phlebitis	72.5%	72.5%	72.5%
	Perempuan	Count	11	11	22
		% within Jenis Kelamin	50.0%	50.0%	100.0%
		% within Kejadian Phlebitis	27.5%	27.5%	27.5%
Total	Count	40	40	80	
	% within Jenis Kelamin	50.0%	50.0%	100.0%	
	% within Kejadian Phlebitis	100.0%	100.0%	100.0%	



Umur * Kejadian Phlebitis

Crosstab

		Kejadian Phlebitis		Total	
		Ya	Tidak		
Umur	Count	4	4	8	
	Remaja Akhir (17-25 Tahun)	% within Umur	50.0%	50.0%	100.0%
		% within Kejadian Phlebitis	10.0%	10.0%	10.0%
	Count	7	7	14	
	Dewasa Awal (26-35 Tahun)	% within Umur	50.0%	50.0%	100.0%
		% within Kejadian Phlebitis	17.5%	17.5%	17.5%
	Count	13	13	26	
	Dewasa Akhir (36-45 Tahun)	% within Umur	50.0%	50.0%	100.0%
		% within Kejadian Phlebitis	32.5%	32.5%	32.5%
	Count	16	16	32	
	Lansia Awal (46-55 Tahun)	% within Umur	50.0%	50.0%	100.0%
		% within Kejadian Phlebitis	40.0%	40.0%	40.0%
Total	Count	40	40	80	
	% within Umur	50.0%	50.0%	100.0%	
	% within Kejadian Phlebitis	100.0%	100.0%	100.0%	

Pendidikan * Plebitis

Crosstab

Count		Plebitis		Total
		Plebitis	Non Plebitis	
Pendidikan	SD	4	4	8
	SMP	6	8	14
	SMA	24	22	46
	Perguruan Tinggi	6	6	12
Total		40	40	80



Pekerjaan * Plebitis

Crosstab

Count

		Plebitis		Total
		Plebitis	Non Plebitis	
Pekerjaan	Wiraswasta	16	16	32
	Buruh	2	2	4
	Pelajar/Mahasiswa	10	10	20
	IRT	11	11	22
	PNS	1	1	2
Total		40	40	80

Lokasi Pemasangan * Kejadian Phlebitis

Crosstab

			Kejadian Phlebitis		Total
			Ya	Tidak	
Lokasi Pemasangan	Vena Metacarpal	Count	40	40	80
		% within Lokasi Pemasangan	50.0%	50.0%	100.0%
		% within Kejadian Phlebitis	100.0%	100.0%	100.0%
Total		Count	40	40	80
		% within Lokasi Pemasangan	50.0%	50.0%	100.0%
		% within Kejadian Phlebitis	100.0%	100.0%	100.0%

Lama Waku Plebitis * Kejadian Phlebitis

Crosstab

			Kejadian Phlebitis		Total
			Ya	Tidak	
60-72 Jam		Count	40	40	80
		% within Lama Waku Plebitis	50.0%	50.0%	100.0%
		% within Kejadian Phlebitis	50.0%	50.0%	100.0%
Total		Count	40	40	80
		% within Lama Waku Plebitis	50.0%	50.0%	100.0%
		% within Kejadian Phlebitis	100.0%	100.0%	100.0%



Ukuran IV Catheter * Kejadian Phlebitis

Crosstab

			Kejadian Phlebitis		Total
			Ya	Tidak	
Ukuran IV Catheter	18	Count	2	2	04
		% within Lama Waku Plebitis	50.0%	50.0%	100.0%
		% within Kejadian Phlebitis	2.5%	2.5%	2.5%
	20	Count	35	35	70
		% within Lama Waku Plebitis	50.0%	50.0%	100.0%
		% within Kejadian Phlebitis	87.5%	87.5%	87.5%
22	Count	3	3	6	
	% within Lama Waku Plebitis	50.0%	50.0%	100.0%	
	% within Kejadian Phlebitis	7.5%	7.5%	7.5%	
Total	Count	40	40	80	
	% within Lama Waku Plebitis	50.0%	50.0%	100.0%	
	% within Kejadian Phlebitis	100.0%	100.0%	100.0%	

Jenis Cairan * Kejadian Phlebitis

Crosstab

			Kejadian Phlebitis		Total
			Ya	Tidak	
Jenis Cairan	Isotonik	Count	40	40	80
		% within Jenis Cairan	50.0%	50.0%	100.0%
		% within Kejadian Phlebitis	50%	50%	100%
Total		Count	40	40	80
		% within Jenis Cairan	50.0%	50.0%	100.0%
		% within Kejadian Phlebitis	100.0%	100.0%	100.0%



JJI VALIDITAS

		Correlations																										
		P1	P2	P3	P4	P5	P6	P7	P8	P9	P10	P11	P12	P13	P14	P15	P16	P17	P18	P19	P20	P21	P22	P23	P24	P25	TOTAL	
P1	Pearson Correlation % (2-tailed) N	1	.397	.308	.883	.315	-.132	-.263	.152	.309	.024	.912	.954	.964	.197	.347	-.130	.133	.386	.133	.197	.165	.391	.389	.152	.163	.413	
P2	Pearson Correlation % (2-tailed) N	.397	1	.915	.216	.028	-.119	-.267	-.119	.880	.051	.994	.244	.244	1.800	.035	.997	-.823	.066	-.820	1.887	.123	.888	.815	-.119	.123	.453	
P3	Pearson Correlation % (2-tailed) N	.308	.915	1	.172	.053	-.882	.232	-.882	.071	.069	1.07	.345	.315	.052	.998	-.889	.071	-.809	.810	.091	.831	1.089	-.982	.881	.489		
P4	Pearson Correlation % (2-tailed) N	.883	.216	.172	1	-.069	1.485	.133	1.485	-.930	1.38	1.94	.885	.965	.216	-.182	.995	.811	-.059	.811	.214	-.982	.832	.172	1.485	-.982	.474	
P5	Pearson Correlation % (2-tailed) N	.315	.028	.053	-.069	1	.826	.018	.026	1.28	-.042	-.935	.285	-.288	.826	1.82	.996	.182	.128	.182	.028	.218	.983	.093	.826	.218	.211	
P6	Pearson Correlation % (2-tailed) N	.132	-.119	-.062	.145	.026	1	.211	1.068	.158	.108	.078	.183	.103	-.119	.145	.144	.878	.158	.876	.119	.070	.887	-.062	1.000	.870	.488	
P7	Pearson Correlation % (2-tailed) N	.267	.267	.232	.133	.018	.211	1	.211	.212	.077	.887	.245	.245	.185	.027	.121	.212	.121	.267	-.071	.884	.232	.211	-.881	.388		
P8	Pearson Correlation % (2-tailed) N	.243	.243	.243	.243	.243	.243	.243	1	.243	.243	.243	.243	.243	.243	.243	.243	.243	.243	.243	.243	.243	.243	.243	.243	.243	.243	
P9	Pearson Correlation % (2-tailed) N	.024	.024	.024	.024	.024	.024	.024	.024	1	-.118	-.124	.216	.216	.880	.833	-.264	-.349	1.088	-.848	.888	.147	.937	.071	.158	.147	.312	
P10	Pearson Correlation % (2-tailed) N	.912	.912	.912	.912	.912	.912	.912	.912	1	.970	.888	.008	.891	-.188	.141	.888	-.116	.898	.081	-.002	-.898	.089	.100	-.882	.271		
P11	Pearson Correlation % (2-tailed) N	.954	.954	.954	.954	.954	.954	.954	.954	.970	1	.970	.888	.008	.891	-.188	.141	.888	-.116	.898	.081	-.002	-.898	.089	.100	-.882	.271	
P12	Pearson Correlation % (2-tailed) N	.197	.347	.345	.315	.052	-.889	.071	-.809	.810	.091	.831	1.089	-.982	.881	.489	-.062	1.000	.870	.488	-.062	1.000	.870	.488	-.062	1.000	.870	.488
P13	Pearson Correlation % (2-tailed) N	.130	.133	.133	.133	.133	.133	.133	.133	.133	.133	.133	.133	.133	.133	.133	.133	.133	.133	.133	.133	.133	.133	.133	.133	.133	.133	
P14	Pearson Correlation % (2-tailed) N	.386	.386	.386	.386	.386	.386	.386	.386	.386	.386	.386	.386	.386	.386	.386	.386	.386	.386	.386	.386	.386	.386	.386	.386	.386	.386	.386
P15	Pearson Correlation % (2-tailed) N	.165	.165	.165	.165	.165	.165	.165	.165	.165	.165	.165	.165	.165	.165	.165	.165	.165	.165	.165	.165	.165	.165	.165	.165	.165	.165	.165
P16	Pearson Correlation % (2-tailed) N	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391
P17	Pearson Correlation % (2-tailed) N	.389	.389	.389	.389	.389	.389	.389	.389	.389	.389	.389	.389	.389	.389	.389	.389	.389	.389	.389	.389	.389	.389	.389	.389	.389	.389	.389
P18	Pearson Correlation % (2-tailed) N	.152	.152	.152	.152	.152	.152	.152	.152	.152	.152	.152	.152	.152	.152	.152	.152	.152	.152	.152	.152	.152	.152	.152	.152	.152	.152	.152
P19	Pearson Correlation % (2-tailed) N	.309	.309	.309	.309	.309	.309	.309	.309	.309	.309	.309	.309	.309	.309	.309	.309	.309	.309	.309	.309	.309	.309	.309	.309	.309	.309	.309
P20	Pearson Correlation % (2-tailed) N	.024	.024	.024	.024	.024	.024	.024	.024	.024	.024	.024	.024	.024	.024	.024	.024	.024	.024	.024	.024	.024	.024	.024	.024	.024	.024	.024
P21	Pearson Correlation % (2-tailed) N	.930	.930	.930	.930	.930	.930	.930	.930	.930	.930	.930	.930	.930	.930	.930	.930	.930	.930	.930	.930	.930	.930	.930	.930	.930	.930	.930
P22	Pearson Correlation % (2-tailed) N	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391	.391
P23	Pearson Correlation % (2-tailed) N	.886	.886	.886	.886	.886	.886	.886	.886	.886	.886	.886	.886	.886	.886	.886	.886	.886	.886	.886	.886	.886	.886	.886	.886	.886	.886	.886
P24	Pearson Correlation % (2-tailed) N	.243	.243	.243	.243	.243	.243	.243	.243	.243	.243	.243	.243	.243	.243	.243	.243	.243	.243	.243	.243	.243	.243	.243	.243	.243	.243	.243
P25	Pearson Correlation % (2-tailed) N	.185	.185	.185	.185	.185	.185	.185	.185	.185	.185	.185	.185	.185	.185	.185	.185	.185	.185	.185	.185	.185	.185	.185	.185	.185	.185	.185
TOTAL	Pearson Correlation % (2-tailed) N	.413	.453	.405	.474	.221	-.409	-.388	-.409	.312	.271	.393	.386	.390	.483	.206	.389	.244	.312	.244	.455	.259	.224	.485	.408	.226	1	

** Correlation is significant at the .01 level (2-tailed).
 * Correlation is significant at the .05 level (2-tailed).



JJI REABILITAS

Reliability Statistics

Cronbach's Alpha	N of Items
.824	25

Item-Total Statistics

	Scale Mean if Item Deleted	Scale Variance if Item Deleted	Corrected Item-Total Correlation	Cronbach's Alpha if Item Deleted
P1	29.68	19.336	.568	.811
P2	29.54	18.986	.521	.811
P3	29.50	18.759	.558	.809
P4	29.65	20.484	.182	.825
P5	29.63	20.060	.288	.821
P6	29.48	19.620	.332	.820
P7	29.71	19.929	.379	.818
P8	29.48	19.620	.332	.820
P9	29.56	19.642	.362	.818
P10	29.60	20.420	.157	.827
P11	29.59	20.347	.171	.826
P12	29.66	19.315	.554	.811
P13	29.66	19.315	.554	.811
P14	29.54	18.986	.521	.811
P15	29.59	19.790	.338	.819
P16	29.74	20.956	.086	.826
P17	29.55	20.200	.212	.825
P18	29.56	19.642	.362	.818
P19	29.55	20.200	.212	.825
P20	29.54	18.986	.521	.811
P21	29.71	20.233	.324	.820
P22	29.61	19.987	.300	.821
P23	29.50	18.759	.558	.809
P24	29.48	19.620	.332	.820
P25	29.71	20.233	.324	.820



Validasi

	Validasi Prevalensi	Reability 1	Reability 2	Reability 3	Reability 4	Reability 5	Assurance 1	Assurance 2	Assurance 3	Assurance 4	Assurance 5	Tangguh 1	Tangguh 2	Tangguh 3	Tangguh 4	Tangguh 5	Cepat 1	Cepat 2	Cepat 3	Cepat 4	Cepat 5	Responsif res 1	Responsif res 2	Responsif res 3	Responsif res 4	Responsif res 5
11. Yang Mening	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Masih	1,00	1,00	1,00	1,00	1,00	1,00	1,00	1,00	1,00	1,00	1,00	1,00	1,00	1,00	1,00	1,00	1,00	1,00	1,00	1,00	1,00	1,00	1,00	1,00	1,00	1,00
Masih	1,00	1,00	2,00	2,00	1,00	1,00	2,00	2,00	2,00	2,00	2,00	2,00	2,00	2,00	1,00	2,00	1,00	1,00	1,00	1,00	1,00	2,00	1,00	1,00	1,00	2,00
100.000000	100.000000	112.000000	112.000000	112.000000	112.000000	112.000000	112.000000	112.000000	112.000000	112.000000	112.000000	112.000000	112.000000	112.000000	112.000000	112.000000	112.000000	112.000000	112.000000	112.000000	112.000000	112.000000	112.000000	112.000000	112.000000	112.000000
Minimum	1	1	1	1	1	1	1	1	1	1	1	2	1	2	1	1	1	1	1	1	1	1	1	1	1	2
Maksimum	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2

Reability 1

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid YA (Tidak sesuai SOP)/ Tidak dilakukan sama sekali	44	55.0	55.0	55.0
Ya (sesuai SOP)	36	45.0	45.0	100.0
Total	80	100.0	100.0	

Reability 2

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid YA (Tidak sesuai SOP)/ Tidak dilakukan sama sekal	1	1.3	1.3	1.3
Ya (Sesuai SOP)	79	98.8	98.8	100.0
Total	80	100.0	100.0	

Reability 3

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid YA (Tidak sesuai SOP)/ Tidak dilakukan sama sekal	2	2.5	2.5	2.5
Ya (Sesuai SOP)	78	97.5	97.5	100.0
Total	80	100.0	100.0	



Reability 4

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	YA (Tidak sesuai SOP)/ Tidak dilakukan sama sekal	45	56.3	56.3
	Ya (Sesuai SOP)	35	43.8	100.0
	Total	80	100.0	100.0

Reability 5

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	YA (Tidak sesuai SOP)/ Tidak dilakukan sama sekal	46	57.5	57.5
	Ya (Sesuai SOP)	34	42.5	100.0
	Total	80	100.0	100.0

Assurance 1

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	YA (Tidak sesuai SOP)/ Tidak dilakukan sama sekal	1	1.3	1.3
	Ya (Sesuai SOP)	79	98.8	100.0
	Total	80	100.0	100.0

Assurance 2

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	YA (Tidak sesuai SOP)/ Tidak dilakukan sama sekal	39	48.8	48.8
	Ya (Sesuai SOP)	41	51.3	100.0
	Total	80	100.0	100.0



Assurance 3

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	YA (Tidak sesuai SOP)/ Tidak dilakukan sama sekali	39	48.8	48.8
	Ya (Sesuai SOP)	41	51.3	100.0
	Total	80	100.0	100.0

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	YA (Tidak sesuai SOP)/ Tidak dilakukan sama sekali	39	48.8	48.8
	Ya (Sesuai SOP)	41	51.3	100.0
	Total	80	100.0	100.0

Assurance 5

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	YA (Tidak sesuai SOP)/ Tidak dilakukan sama sekali	1	1.3	1.3
	Ya (Sesuai SOP)	79	98.8	100.0
	Total	80	100.0	100.0

Tangible 1

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya (Sesuai SOP)	80	100.0	100.0

Tangible 2

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	YA (Tidak sesuai SOP)/ Tidak dilakukan sama sekali	41	51.3	51.3
	Ya (Sesuai SOP)	39	48.8	100.0
	Total	80	100.0	100.0



Tangible 3

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Ya (Sesuai SOP)	80	100.0	100.0	100.0

Tangible 4

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid YA (Tidak sesuai SOP)/ Tidak dilakukan sama sekali	41	51.3	51.3	51.3
Ya (Sesuai SOP)	39	48.8	48.8	100.0
Total	80	100.0	100.0	

Tangible 5

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid YA (Tidak sesuai SOP)/ Tidak dilakukan sama sekali	41	51.3	51.3	51.3
Ya (Sesuai SOP)	39	48.8	48.8	100.0
Total	80	100.0	100.0	

Empathy 1

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid YA (Tidak sesuai SOP)/ Tidak dilakukan sama sekali	43	53.8	53.8	53.8
Ya (Sesuai SOP)	37	46.3	46.3	100.0
Total	80	100.0	100.0	

Empathy 2

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid YA (Tidak sesuai SOP)/ Tidak dilakukan sama sekali	43	53.8	53.8	53.8
Ya (Sesuai SOP)	37	46.3	46.3	100.0
Total	80	100.0	100.0	



Empathy 3

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	YA (Tidak sesuai SOP)/ Tidak dilakukan sama sekali	43	53.8	53.8
	Ya (Sesuai SOP)	37	46.3	100.0
	Total	80	100.0	100.0

Empathy 4

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	YA (Tidak sesuai SOP)/ Tidak dilakukan sama sekali	43	53.8	53.8
	Ya (Sesuai SOP)	37	46.3	100.0
	Total	80	100.0	100.0

Empathy 5

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	YA (Tidak sesuai SOP)/ Tidak dilakukan sama sekali	1	1.3	1.3
	Ya (Sesuai SOP)	79	98.8	100.0
	Total	80	100.0	100.0

Responsivennes 1

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya (Tidak sesuai SOP)/ Tidak dilakukan sama sekali	44	55.0	55.0
	Ya (Sesuai SOP)	36	45.0	100.0
	Total	80	100.0	100.0



Responsivennes 2

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	YA (Tidak sesuai SOP)/ Tidak dilakukan sama sekali	44	55.0	55.0
	Ya (Sesuai SOP)	36	45.0	100.0
	Total	80	100.0	100.0

Responsivennes 4

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	YA (Tidak sesuai SOP)/ Tidak dilakukan sama sekali	44	55.0	55.0
	Ya (Sesuai SOP)	36	45.0	100.0
	Total	80	100.0	100.0

Responsivennes 5

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Ya (Sesuai SOP)	80	100.0	100.0	100.0

UJI NORMALITAS

Tests of Normality

	Kejadian Phelebitis	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
Kualitas Layanan	Ya	.210	40	.000	.910	40	.004
	Tidak	.091	40	.200*	.958	40	.147
IL 6	Ya	.202	40	.000	.859	40	.000
	Tidak	.261	40	.000	.826	40	.000
VITAMIN D RESEPTOR	Ya	.284	40	.000	.717	40	.000
	Tidak	.211	40	.000	.887	40	.001

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction



UJI MANN WHITNEY KUALITAS LAYANAN TERHADAP KEJADIAN PLEBITIS

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
Kualitas Layanan	80	40.9500	5.00607	33.00	50.00
Kejadian Phelebitis	80	1.5000	.50315	1.00	2.00

Ranks

	Kejadian Phelebitis	N	Mean Rank	Sum of Ranks
Kualitas Layanan	Ya	40	31.81	1272.50
	Tidak	40	49.19	1967.50
Total		80		

Test Statistics^a

	Kualitas Layanan
Mann-Whitney U	452.500
Wilcoxon W	1272.500
Z	-3.369
Asymp. Sig. (2-tailed)	.001

a. Grouping Variable: Kejadian Phelebitis

UJI MANN WHITNEY VITAMIN D RESEPTOR TERHADAP KEJADIAN PLEBITIS

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
VITAMIN D RESEPTOR	80	20.0491	8.87204	8.85	32.35
Kejadian Phelebitis	80	1.5000	.50315	1.00	2.00

Ranks

	Kejadian Phelebitis	N	Mean Rank	Sum of Ranks
VITAMIN D RESEPTOR	Ya	40	20.50	820.00
	Tidak	40	60.50	2420.00
Total		80		

Test Statistics^a



	VITAMIN D RESEPTOR
Mann-Whitney U	.000
Wilcoxon W	820.000
Z	-7.699
Asymp. Sig. (2-tailed)	.000

a. Grouping Variable: Kejadian Phelebitis

UJI MANN WHITNEY IL-6 TERHADAP KEJADIAN PLEBITIS

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
IL 6	80	1061.8353	340.67313	644.23	1503.73
Kejadian Phelebitis	80	1.5000	.50315	1.00	2.00

Ranks

	Kejadian Phelebitis	N	Mean Rank	Sum of Ranks
IL 6	Ya	40	60.50	2420.00
	Tidak	40	20.50	820.00
	Total	80		

Test Statistics^a

	IL 6
Mann-Whitney U	.000
Wilcoxon W	820.000
Z	-7.699
Asymp. Sig. (2-tailed)	.000

a. Grouping Variable: Kejadian
Phelebitis



ANOVA^a

Model		Sum of Squares	df	Mean Square	F	Sig.
1	Regression	18.844	3	6.281	413.110	.000 ^b
	Residual	1.156	76	.015		
	Total	20.000	79			
2	Regression	18.808	2	9.404	607.651	.000 ^c
	Residual	1.192	77	.015		
	Total	20.000	79			

a. Dependent Variable: Kejadian Phelebitis

b. Predictors: (Constant), IL 6, KUALITAS LAYANAN, VITAMIN D RESEPTOR

c. Predictors: (Constant), IL 6, VITAMIN D RESEPTOR

Coefficients^a

Model		Unstandardized Coefficients		Standardized Coefficients	t
		B	Std. Error	Beta	
1	(Constant)	1.848	.282		6.560
	KUALITAS LAYANAN	.005	.003	.047	1.540
	VITAMIN D RESEPTOR	.020	.005	.361	4.434
	IL 6	-.001	.000	-.606	-7.208
2	(Constant)	2.131	.215		9.900
	VITAMIN D RESEPTOR	.019	.005	.337	4.178
	IL 6	-.001	.000	-.647	-8.020



Coefficients^a

Model		Sig.
1	(Constant)	.000
	KUALITAS LAYANAN	.128
	VITAMIN D RESEPTOR	.000
	IL 6	.000
2	(Constant)	.000
	VITAMIN D RESEPTOR	.000
	IL 6	.000

a. Dependent Variable: Kejadian Phelebitis

Kejadian Phelebitis * Jenis Cairan Crosstabulation

		Jenis Cairan				Total	
		Nacl	Ringer Laktat	Asering	D5%		
Kejadian Phelebitis	Ya	Count	18	18	2	2	40
		% within Kejadian Phelebitis	45.0%	45.0%	5.0%	5.0%	100.0%
		% within Jenis Cairan	47.4%	52.9%	50.0%	50.0%	50.0%
	Tidak	Count	20	16	2	2	40
		% within Kejadian Phelebitis	50.0%	40.0%	5.0%	5.0%	100.0%
		% within Jenis Cairan	52.6%	47.1%	50.0%	50.0%	50.0%
Total	Count	38	34	4	4	80	
	% within Kejadian Phelebitis	47.5%	42.5%	5.0%	5.0%	100.0%	
	% within Jenis Cairan	100.0%	100.0%	100.0%	100.0%	100.0%	



Kejadian Phelebitis * Derajat Plebitis Crosstabulation

		Derajat Plebitis				Total	
		Derajat 1	Derajat 2	Derajat 3	Derajat 4		
Kejadian Phelebitis	Ya	Count	0	5	33	2	40
		% within Kejadian Phelebitis	0.0%	12.5%	82.5%	5.0%	100.0%
		% within Derajat Plebitis	0.0%	31.3%	54.1%	100.0%	50.0%
	Tidak	Count	1	11	28	0	40
		% within Kejadian Phelebitis	2.5%	27.5%	70.0%	0.0%	100.0%
		% within Derajat Plebitis	100.0%	68.8%	45.9%	0.0%	50.0%
Total	Count	1	16	61	2	80	
		% within Kejadian Phelebitis	1.3%	20.0%	76.3%	2.5%	100.0%
		% within Derajat Plebitis	100.0%	100.0%	100.0%	100.0%	100.0%

ODDS RATIO

Reability

Mantel-Haenszel Common Odds Ratio Estimate

Estimate		2.579
ln(Estimate)		.947
Std. Error of ln(Estimate)		.468
Asymp. Sig. (2-sided)		.042
	Common Odds Ratio	Lower Bound 1.030
Asymp. 95% Confidence Interval		Upper Bound 6.457
	ln(Common Odds Ratio)	Lower Bound .030
		Upper Bound 1.865

The Mantel-Haenszel common odds ratio estimate is asymptotically normally distributed under the common odds ratio of 1.000 assumption. So is the natural log of the estimate.



Assurance

Mantel-Haenszel Common Odds Ratio Estimate

Estimate			2.513
ln(Estimate)			.921
Std. Error of ln(Estimate)			.461
Asymp. Sig. (2-sided)			.045
Asymp. 95% Confidence Interval	Common Odds Ratio	Lower Bound	1.019
		Upper Bound	6.198
Interval	ln(Common Odds Ratio)	Lower Bound	.018
		Upper Bound	1.824

The Mantel-Haenszel common odds ratio estimate is asymptotically normally distributed under the common odds ratio of 1.000 assumption. So is the natural log of the estimate.

Tangibel

Mantel-Haenszel Common Odds Ratio Estimate

Estimate			2.786
ln(Estimate)			1.025
Std. Error of ln(Estimate)			.463
Asymp. Sig. (2-sided)			.026
Asymp. 95% Confidence Interval	Common Odds Ratio	Lower Bound	1.125
		Upper Bound	6.899
Interval	ln(Common Odds Ratio)	Lower Bound	.118
		Upper Bound	1.931

The Mantel-Haenszel common odds ratio estimate is asymptotically normally distributed under the common odds ratio of 1.000 assumption. So is the natural log of the estimate.

Empathy

Mantel-Haenszel Common Odds Ratio Estimate

Estimate			3.115
ln(Estimate)			1.136
Std. Error of ln(Estimate)			.467
Asymp. Sig. (2-sided)			.014
Asymp. 95% Confidence Interval	Common Odds Ratio	Lower Bound	1.247
		Upper Bound	7.781
Interval	ln(Common Odds Ratio)	Lower Bound	.221
		Upper Bound	2.052

The Mantel-Haenszel common odds ratio estimate is asymptotically normally distributed under the common odds ratio of 1.000 assumption. So is the natural log of the estimate.



Responsiveness

Mantel-Haenszel Common Odds Ratio Estimate

Estimate			3.157
ln(Estimate)			1.150
Std. Error of ln(Estimate)			.470
Asymp. Sig. (2-sided)			.013
Asymp. 95% Confidence Interval	Common Odds Ratio	Lower Bound	1.255
		Upper Bound	7.938
Interval	ln(Common Odds Ratio)	Lower Bound	.227
		Upper Bound	2.072

The Mantel-Haenszel common odds ratio estimate is asymptotically normally distributed under the common odds ratio of 1.000 assumption. So is the natural log of the estimate.



Lampiran 7 :

Dokumentasi Penelitian





1. Kit Elisa Andi Mappanganro, S.Kep., Ns., M.Kep



2. Human Vitamin D Receptor / VDR ELISA Kit Catalog No. LS-F33483





3. Human IL-6/ Interleukin 6 Elisa Kit Catalog NO. LS-F9982



4. Layout sample in plate


Name : Andi Mappanganro
 Date : 23 Oktober 2023
 Plate : 1
 Assay : Human Vitamin D Receptor / VDR ELISA Kit Catalog No: LS-F33483

	1	2	3	4	5	6	7	8	9	10	11	12
A	STD-1	STD-1	P01	P01	P02	P02	P03	P03	P04	P04	P05	P05
B	STD-2	STD-2	P06	P06	P07	P07	P08	P08	P09	P09	P010	P010
C	STD-3	STD-3	P11	P11	P12	P12	P13	P13	P14	P14	P15	P15
D	STD-4	STD-4	P16	P16	P17	P17	P18	P18	P19	P19	P20	P20
E	STD-5	STD-5	NP01	NP01	NP02	NP02	NP03	NP03	NP04	NP04	NP5	NP5
F	STD-6	STD-6	NP06	NP06	NP07	NP07	NP08	NP08	NP09	NP09	NP10	NP10
G	STD-7	STD-7	NP11	NP11	NP12	NP12	NP13	NP13	NP14	NP14	NP15	NP15
H	ZERO	ZERO	NP16	NP16	NP17	NP17	NP18	NP18	NP19	NP19	NP20	NP20

Lab. Tech. : Romi
 Remarks :



5. Prepare all reagents, samples and standards



6. Add 100uL standard or sample to each well






7. Incubate for 1 hour at 37C




8. Remove the liquid. Add 100uL Biotinylated. Incubate for 1 hour at 37C






9. Aspirate and wash 3 times




10. Add 100uL Detection HRP and Incubate for 30 min at 37C





11. Aspirate and wash 5 times




12. Add 90uL TMB Substrate Reagent. Incubate for 10-20 min at 37C






13. Plate after 15 min substrate




14. Add 50uL Stop Solution. Blue color to yellow color





15. Plate after stop reaction



16. Read at 45nm Immediately and calculation of results



Lampiran 8 :

Surat Keterangan Penelitian


PEMERINTAH PROVINSI SULAWESI SELATAN
DINAS KESEHATAN
UPT. RUMAH SAKIT UMUM DAERAH LABUANG BAJI
Jl. Dr. Ratulangi MD, 81 Telp. 873482 - 872120 - 872836 - 874664 Fax : 0411-833454
E-mail: rumsakit@labuangbaji.go.id
MAKASSAR

SURAT KETERANGAN
Nomor : 800.2/112/LB-01.3/XII/2024

Yang bertanda tangan dibawah ini :

Nama : **Dr. Zainuddin, SKM, S.Kep, Ns, M.Kes**
NIP : 19730319 199303 1 006
Pangkat/Golongan : Pembina IV/a
Jabatan : Kepala Bidang Pendidikan, Penelitian
Dan Inovasi

Dengan ini menerangkan bahwa :

Nama : Andi Mappanganro
Nomor Pokok : C013201003
Program Studi : S-3 Ilmu Kedokteran
Alamat : Jl. Perintis Kemerdekaan Km 10 Makassar

Bahwa nama tersebut di atas telah melakukan Penelitian dari bulan Januari s.d Desember 2023 di Rumah Sakit Umum Daerah Labuang Baji dalam rangka Penyelesaian tugas akhir Tesis dengan judul "**NALISIS KUALITAS LAYANAN KEPERAWATAN DAN KADAR VITAMIN D RESEPTOR, INTERLEUKIN 6 TERHADAP KEJADIAN PLEBITIS PADA PASIEN TERPASANG INFUS DI RS LABUANG BAJI DAN RS IBNU SINA MAKASSAR** "

Demikian surat keterangan ini dibuat untuk dipergunakan seperlunya.

Makassar, 27 Desember 2023
Kepala Bidang
Pendidikan, Penelitian dan Inovasi


Dr. Zainuddin, SKM., S.Kep., Ns., M.Kes
NIP. 19730319 199303 1 006



"IBNU SINA" HOSPITAL
TEACHING HOSPITAL
OF UMI FOUNDATION



مستشفى ابن سينا
مؤسسة الإرفاق
لجامعة المسلمين الدولية

RUMAH SAKIT "IBNU SINA" YW-UMI MAKASSAR
Jl. Urip Sumaharjo km 5 no. 364 Telp. (0411) 452917/452958 Fax (0411) 425397

SURAT KETERANGAN

No : 001/B.09/II.2/RS IBNU SINA/II/2024

Kami yang bertanda tangan di bawah ini menerangkan bahwa yang tersebut namanya di bawah ini :

Nama : Andi Mappanganro
NIM : C013201003
Judul : Analisis Kualitas Layanan Keperawatan dan Kadar Vitamin D Reseptor, Interleukin 6 Terhadap kejadian Plebitis Pada Pasien terpasang Infus di RS. Labuang Baji dan RS. Ibnu Sina Makassar.

Benar yang tersebut namanya di atas telah selesai melakukan Penelitian di RUMAH SAKIT IBNU SINA YW-UMI pada tanggal 13-27 Juni 2023.

Demikian surat ini diberikan untuk dipergunakan sebagaimana mestinya.

Makassar 19 Februari 2024

Mengetahui,
Direktur Pendidikan & SDM

Kabid. Penelitian, Publikasi & Peng. Masyarakat

Dr. dr. Shofiyah Latief, M.Kes, Sp.Rad(K)-PRP, dr. Sidrah Darma, Sp.A

Cc. Arsip



KEMENTERIAN PENDIDIKAN KEBUDAYAAN RISET TEKNOLOGI
FAKULTAS KEDOKTERAN, UNIVERSITAS HASANUDDIN
Bagian Mikrobiologi, Laboratorium Biologi Molekuler dan Imunologi
Jl. Perintis Kemerdekaan, Kampus Tamalanrea, KM.10, Makassar, 90245

Telp/Fax : +62-411-586971

SURAT KETERANGAN

No. : 21/LBMI-FK/XII/2023

Hal. : Penelitian

Yang bertanda tangan dibawah ini :

Nama : Prof. dr. Mochammad Hatta, Ph.D., Sp.MK (K).
NIP : 195704161983041001
Jabatan : Kepala Laboratorium Biologi Molekuler & Imunologi
Bagian Mikrobiologi, Fakultas Kedokteran, UNHAS

Menerangkan bahwa

Nama Peneliti : Andi Mappanganro
NIM : C013201003

Benar telah menyelesaikan penelitian di laboratorium Biologi Molekuler & Imunologi, Fakultas Kedokteran, Universitas Hasanuddin dengan judul *"Analisis kualitas layanan perawat dan kadar Vitamin D Reseptor, Interleukin 6 terhadap kejadian Phlebitis pada pasien terpasang infus di RS Ibnu Sina dan RS Labuang Baji"*. Demikianlah surat keterangan ini dibuat untuk dipergunakan sebagaimana mestinya.

Makassar, 18 Desember 2023,

Kepala Laboratorium Biologi Molekuler

Fakultas Kedokteran, UNHAS



(Signature)
Prof. dr. Mochammad Hatta, Ph.D., Sp.MK (K)